PODCAST · science
Lung Cancer Update
by Dr. Neil Love
Featuring one-on-one interviews conducted by Dr Neil Love, this series bridges the gap between research and patient care by providing medical oncologists, hematologists and hematology/oncology fellows ongoing access to the perspectives and opinions of national and international research leaders with an expertise in thoracic oncology.
-
50
First-Line and Maintenance Therapy for Patients with Extensive-Stage Small Cell Lung Cancer — An Interview with Prof Martin Reck
Featuring an interview with Prof Martin Reck, including the following topics:Case: A woman in her mid 70s with extensive-stage small cell lung cancer (ES-SCLC) experiences a strong response to first-line chemoimmunotherapy and maintenance lurbinectedin/atezolizumab (0:00)Biology of small cell lung cancer and pharmacodynamics of systemic treatment (3:25)Considerations with maintenance therapy for ES-SCLC (9:31)Considerations with immunotherapy for ES-SCLC (13:12)Curability of SCLC with systemic therapy (15:17)Data with chemoimmunotherapy for patients with poor performance status (25:55)Future developments in therapy for SCLC (30:11)Rapid fire: Small Cell 101 (35:45)CME information and select publications
-
49
Small Cell Lung Cancer — Year in Review Series on Relevant New Datasets and Advances
Dr Christine L Hann from the Johns Hopkins University School of Medicine in Baltimore, Maryland, and Dr Jacob Sands from Dana-Farber Cancer Institute in Boston, Massachusetts, discuss key clinical trial data surrounding the management of SCLC.CME information and select publications
-
48
EGFR-Mutant Non-Small Cell Lung Cancer — Year in Review Series on Relevant New Datasets and Advances
Dr Suresh S Ramalingam and Dr Helena Yu discuss the selection and sequencing of therapy for patients with EGFR mutation-positive non-small cell lung cancer and summarize major advances in the treatment landscape reported over the past year. CME information and select publications here.
-
47
Lung Cancer — 5-Minute Journal Club with Dr Natalie Vokes: Current and Future Role of Tumor-Informed Circulating Tumor DNA Assays
Dr Natalie Vokes from The University of Texas MD Anderson Cancer Center in Houston discusses recent developments with circulating tumor DNA assays in the management of lung cancer. CME information and select publications here.
-
46
Extensive-Stage Small Cell Lung Cancer — Current Patterns of Care with First-Line and Maintenance Therapy
Dr Hossein Borghaei from Fox Chase Cancer Center in Philadelphia, Pennsylvania, and Dr Anne Chiang from Yale Cancer Center in New Haven, Connecticut, discuss key clinical trial data in the first-line management of ES-SCLC, real-world case studies and current patterns of care among oncologists.CME information and select publications here.
-
45
Extensive-Stage Small Cell Lung Cancer — What Clinicians Want to Know About First-Line and Maintenance Therapy
Dr Luis Paz-Ares from the Spanish National Oncology Research Center in Madrid and Dr Shields from Indiana University School of Medicine in Indianapolis discuss key datasets surrounding first-line and maintenance therapy for patients with extensive-stage small cell lung cancer and their clinical implications. CME information and select publications here.
-
44
Lung Cancer — Proceedings from a Symposium Held in Partnership with the American Oncology Network
Dr Justin F Gainor, Dr Corey J Langer and Dr Misty Dawn Shields summarize the treatment landscape and review relevant clinical datasets for patients with lung cancer.CME information and select publications here.
-
43
HER2-Altered Non-Small Cell Lung Cancer — An Interview with Dr John V Heymach
Dr John Heymach from The University of Texas MD Anderson Cancer Center in Houston discusses recent updates on available and novel treatment strategies for HER2-altered non-small cell lung cancer. CME information and select publications here.
-
42
Lung Cancer — 5-Minute Journal Club Issue 4 with Dr Aaron Lisberg: Defining the Role of TROP2-Directed Antibody-Drug Conjugates
Dr Aaron Lisberg from the University of California, Los Angeles, discusses recent developments with TROP2-directed antibody-drug conjugates in the management of non-small cell lung cancer. CME information and select publications here.
-
41
Lung Cancer — 5-Minute Journal Club Issue 3 with Dr Aaron Lisberg: Defining the Role of TROP2-Directed Antibody-Drug Conjugates
Dr Aaron Lisberg from the University of California, Los Angeles discusses recent developments with TROP2-directed antibody-drug conjugates in the management of non-small cell lung cancer. CME information and select publications here.
-
40
Non-Small Cell Lung Cancer — 5-Minute Journal Club Issue 2 with Dr Jacob Sands: Defining the Role of TROP2-Directed Antibody-Drug Conjugates
Dr Jacob Sands from Dana-Farber Cancer Institute in Boston, Massachusetts, discusses recent developments with TROP2-directed antibody-drug conjugates in the management of lung cancer. CME information and select publications here.
-
39
Small Cell Lung Cancer — Expert Perspectives on Actual Patient Cases
Dr Stephen V Liu from Georgetown University Hospital in Washington, DC and Dr Charles Rudin from Memorial Sloan Kettering Cancer Center in New York discuss the role of approved and novel investigational therapies for patients with limited-stage and extensive-stage small cell lung cancer. CME information and select publications here.
-
38
Non-Small Cell Lung Cancer — 5-Minute Journal Club Issue 1 with Dr Jacob Sands: Defining the Role of TROP2-Directed Antibody-Drug Conjugates
Dr Jacob Sands from Dana-Farber Cancer Institute in Boston, Massachusetts, discusses recent developments with TROP2-directed antibody-drug conjugates in the management of non-small cell lung cancer. CME information and select publications here.
-
37
Non-Small Cell Lung Cancer — Year in Review Series on Relevant New Datasets and Advances
Dr Benjamin Levy from Johns Hopkins Sidney Kimmel Cancer Center at Sibley Memorial in Washington, DC, discusses important efficacy and safety data from 2024 related to the use of approved and investigational therapies for localized and advanced non-small cell lung cancer without a targetable mutation. CME information and select publications here.
-
36
Lung Cancer — Proceedings from a Session Held During the 2025 ASCO Annual Meeting on the Current and Future Role of Immunotherapy and Antibody-Drug Conjugates
Prof Marina Garassino, Dr John Heymach, Prof Solange Peters and moderator Dr Jacob Sands present key data from the ASCO 2025 Annual Meeting on the management of metastatic NSCLC without targetable mutations, as well as emerging evidence on the role of antibody-drug conjugates for patients with select actionable genomic alterations. CME information and select publications here.
-
35
For Oncology Nurses: DLL3-Targeting Bispecific T-Cell Engagers for Small Cell Lung Cancer — Proceedings from the 2025 Annual ONS Congress
Dr Anne Chiang, Dr Erin Schenk, and nurse practitioners Ms Elizabeth Krueger and Ms Beth Sandy discuss the role of bispecific antibodies in the management of small cell lung cancer and strategies to mitigate and manage treatment-emergent adverse events. NCPD information and select publications here.
-
34
EGFR Mutation-Positive Non-Small Cell Lung Cancer — Proceedings from a Session Held During the 2025 ASCO Annual Meeting
Prof Nicolas Girard, Dr Jonathan Goldman, Dr Pasi Jänne, Dr Suresh Ramalingam, Dr Joshua Sabari and moderator Dr Helena Yu present data informing treatment decision-making for EGFR-mutated NSCLC at the 2025 ASCO annual meeting. CME information and select publications here.
-
33
Non-Small Cell Lung Cancer and Therapeutic Targets Beyond EGFR — Year in Review Series on Relevant New Datasets and Advances
Dr Jessica J Lin from Massachusetts General Hospital in Boston and Dr Joel W Neal from Stanford Cancer Institute in California summarize major treatment advances over the past year and review relevant ongoing clinical trials using targeted therapies for patients with non-small cell lung cancer. CME information and select publications here.
-
32
Immunotherapy and Nontargeted Approaches for NSCLC — Fourth Annual National General Medical Oncology Summit
Clinical investigators discuss available data guiding the management of non-small cell lung cancer with immunotherapy and other nontargeted approaches. CME information and select publications here.
-
31
EGFR Mutation-Positive NSCLC — Fourth Annual National General Medical Oncology Summit
Clinical investigators discuss available data guiding the management of EGFR mutation-positive non-small cell lung cancer. CME information and select publications here.
-
30
For Oncology Nurses: Antibody-Drug Conjugates for Breast Cancer and Lung Cancer — Proceedings from the 2025 Annual ONS Congress
Dr Edward B Garon, Dr Tiffany A Traina, and nurse practitioners Ms Marianne J Davies and Ms Marissa Marti-Smith discuss the role of antibody-drug conjugates in the care of patients with breast and lung cancer and strategies to mitigate and manage treatment-emergent adverse events. NCPD information and select publications here.
-
29
First-Line Therapy for Metastatic Non-Small Cell Lung Cancer and an ALK Rearrangement — An Interview with Dr Justin F Gainor
Dr Justin F Gainor from Massachusetts General Hospital in Boston reviews available clinical data on ALK inhibitors and first-line treatment strategies for ALK-positive metastatic non-small cell lung cancer. CME information and select publications here.
-
28
EGFR-Mutant Non-Small Cell Lung Cancer — Year in Review Series on Relevant New Datasets and Advances
Dr Enriqueta Felip from the Vall d’Hebron Institute of Oncology in Barcelona, Spain, and Dr Helena Yu from Memorial Sloan Kettering Cancer Center in New York, New York, discuss current and emerging treatment approaches for patients with EGFR-mutant non-small cell lung cancer. CME information and select publications here
-
27
Cases from the Community: Integrating New Research Findings into Current Practice — Lung Cancer
Dr Edward B Garon shares his perspectives on the evolving therapeutic landscape for patients with lung cancer.
-
26
Meet The Professor: Current and Future Use of Nontargeted Therapy for Metastatic Non-Small Cell Lung Cancer — A 2024 World Conference on Lung Cancer
Dr Heather Wakelee from Stanford University School of Medicine in California discusses the implications of recent datasets for the current and future use of nontargeted therapy for metastatic non-small cell lung cancer.
-
25
The Implications of Recent Datasets for the Current and Future Management of Lung Cancer — A Review of Information from ESMO Congress 2024 and Other Conferences
Dr Suresh S Ramalingam from the Emory University School of Medicine in Atlanta, Georgia and Dr Gregory J Riely from Memorial Sloan Kettering Cancer Center in New York, New York discuss the implications of recent data sets for the current and future management of lung cancer.
-
24
Data + Perspectives: Clinical Investigators Explore the Application of Recent Datasets in Current Oncology Care — Lung Cancer
Specialist clinical investigators share their perspectives on the evolving therapeutic landscape for patients with lung cancer.
-
23
Oncology Today with Dr Neil Love: Special Edition — Key Presentations on Lung Cancer from Recent Major Conferences
Dr Stephen V Liu from Georgetown University Hospital in Washington, DC, reviews recently presented data with and newly approved therapies for localized and advanced lung cancers.
-
22
The Implications of Recent Datasets for the Current and Future Management of Small Cell Lung Cancer — A 2024 World Conference on Lung Cancer Review
Dr Jacob Sands from the Dana-Farber Cancer Institute in Boston, Massachusetts, discusses recent presentations on approved and investigational therapies in small cell lung cancer from the 2024 World Conference on Lung Cancer.
-
21
The Implications of Recent Datasets for the Current and Future Use of Nontargeted Therapy for Metastatic Non-Small Cell Lung Cancer
Dr Edward Garon from UCLA Health Jonsson Comprehensive Cancer Center and Dr Luis Paz-Ares from the Spanish National Oncology Research Center in Madrid share their perspectives on recent datasets from the 2024 World Conference on Lung Cancer on the management of non-small cell lung cancer without actionable genomic alterations.
-
20
The Implications of Recent Datasets for the Current and Future Management of Non-Small Cell Lung Cancer with Actionable Targets Beyond EGFR
Dr Ibiayi Dagogo-Jack from Massachusetts General Hospital in Boston and Dr Corey J Langer from the Abramson Cancer Center in Philadelphia, Pennsylvania, discuss the implications of recent datasets for the current and future management of non-small cell lung cancer with actionable targets beyond EGFR.
-
19
The Implications of Recent Datasets for the Current and Future Management of Non-Small Cell Lung Cancer with EGFR Mutations
Dr Joshua K Sabari from the NYU Langone Health Perlmutter Cancer Center and Dr Helena Yu from Memorial Sloan Kettering Cancer Center in New York, New York, summarize the treatment landscape for non-small cell lung cancer with EGFR mutations.
-
18
Inside the Issue: Optimizing the Diagnosis and Treatment of Neuroendocrine Tumors
Dr Pamela Kunz from the Yale School of Medicine and Yale Cancer Center in New Haven, Connecticut, and Dr Simron Singh from the Odette Cancer Centre and Sunnybrook Health Sciences Centre in Toronto, Ontario, Canada, discuss optimizing the diagnosis and treatment of neuroendocrine tumors.
-
17
Striving for Consensus: Current and Future Management of Non-Small Cell Lung Cancer with an EGFR Mutation
Dr Pasi Jänne from the Dana-Farber Cancer Institute in Boston, Massachusetts, Prof Tom John from the Peter MacCallum Cancer Centre in Melbourne, Australia, Dr Zofia Piotrowska from Massachusetts General Hospital in Boston, Massachusetts, and Dr Alexander Spira from the Virginia Cancer Specialists Research Program in Fairfax, discuss recent updates on available and emerging treatment strategies for non-small cell lung cancer with an EGFR mutation.
-
16
Inside the Issue: Integrating ALK-Targeted Therapy into the Management of Localized Non-Small Cell Lung Cancer
Prof Solange Peters from the Lausanne University Hospital in Lausanne, Switzerland, and Professor Ben Solomon from the Peter MacCallum Cancer Centre in Melbourne, Australia, discuss treatment approaches for ALK-rearranged non-small cell lung cancer in the localized disease setting.
-
15
Oncology Today with Dr Neil Love: Novel Agents and Strategies in Lung Cancer
Dr Melissa Johnson from Sarah Cannon Research Institute in Nashville, Tennessee, Dr Ticiana Leal from Winship Cancer Institute of Emory University in Atlanta, Georgia, and Dr Manish Patel from Florida Cancer Specialists & Research Institute in Sarasota, Florida, summarize recently presented advancements, including novel strategies, in the treatment of lung cancer.
-
14
Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Immunotherapy and Other Nontargeted Approaches for Lung Cancer
Dr Matthew Gubens from the University of California, San Francisco summarizes important 2023 datasets guiding the use of immunotherapy and other nontargeted approaches for patients with NSCLC and no actionable mutations.
-
13
Oncology Today with Dr Neil Love: An interview with Jonathan W Goldman, MD — Management of Non-Small Cell Lung Cancer with an EGFR Mutation
Dr Jonathan W Goldman from UCLA Health in Santa Monica, California summarizes recent developments presented at ASCO 2024 for patients with non-small cell lung cancer with an EGFR mutation.
-
12
Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Targeted Therapy for Non-Small Cell Lung Cancer
Dr Justin F Gainor from Massachusetts General Hospital in Boston and Dr Karen Reckamp from Cedars-Sinai Center in Los Angeles, California, summarize recently presented data on targeted therapy strategies for non-small cell lung cancer harboring actionable therapeutic targets.
-
11
Oncology Today with Dr Neil Love: The Emerging Role of B7-H3-Targeted Antibody-Drug Conjugates
Dr Manish Patel from the Florida Cancer Specialists & Research Institute in Sarasota, Florida, discusses drug development, early-phase clinical trials and the emerging field of B7-H3-targeted antibody-drug conjugates for solid tumors.
-
10
Oncology Today with Dr Neil Love: Promising Therapeutic Strategies for Patients with Progressive Metastatic Non-Small Cell Lung Cancer
Dr Melissa Johnson from Sarah Cannon Research Institute in Nashville, Tennessee, discusses available data with antibody-drug conjugates with established and investigational targets in patients with non-small cell lung cancer.
-
9
Implications of Recent Data Sets for the Current and Future Management of Lung Cancer
Dr Luis Paz-Ares from the National Oncology Research Center in Madrid, Spain, Dr Zofia Piotrowska from Massachusetts General Hospital in Boston, and Dr David R Spigel from the Sarah Cannon Research Institute in Nashville, Tennessee, discuss key presentations from the 2023 ESMO Congress for the management of lung cancer.
-
8
Inside the Issue: Integrating Targeted and Immunotherapy into the Management of Localized Non-Small Cell Lung Cancer
Dr Jamie Chaft and Dr John Heymach discuss the optimal integration of targeted therapy and immunotherapy into the care of patients with localized non-small cell lung cancer.
-
7
Striving for Consensus: Current and Future Management of Metastatic Non-Small Cell Lung Cancer in Patients Who Experience Disease Progression on Immune Checkpoint Inhibitor Therapy
Dr Corey Langer, Dr Ticiana Leal, Dr Karen Reckamp and Dr Jacob Sands discuss the optimal current management of relapsed NSCLC and provide perspectives on the future of care for patients with this disease.
-
6
Oncology Today with Dr Neil Love: Special Edition — Key Presentations on Lung Cancer from the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
Featuring a discussion on key presentations on lung cancer from the 2023 ASCO Annual Meeting, with Dr Matthew Gubens, moderated by Dr Neil Love.
-
5
Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Immunotherapy and Other Nontargeted Approaches for Lung Cancer
Proceedings from our Year in Review webinar on immunotherapy and other nontargeted approaches for lung cancer. Featuring perspectives from Drs Luis Paz-Ares and Heather Wakelee, moderated by Dr Neil Love.
-
4
Recent Advances and Future Directions in Lung Cancer — With Dr Ibiayi Dagogo-Jack and Stephen Liu (Proceedings from a Symposium in Partnership with NCOA and SCOS)
Proceedings from a daylong symposium hosted in partnership with North Carolina Oncology Association and the South Carolina Oncology Society, featuring key clinical presentations and papers in breast cancer, gastrointestinal cancers, genitourinary cancers, chronic lymphocytic leukemia and lymphomas, gynecologic cancers and lung cancer. Featuring perspectives from Drs Tanios Bekaii-Saab, Michael Birrer, Danielle Brander, Harold Burstein, Ibiayi Dagogo-Jack, Virginia Kaklamani, Stephen Liu, Ursula Matulonis, Rutika Mehta, Craig Moskowitz, Daniel Petrylak and Sandy Srinivas.
-
3
Striving for Consensus on the Management of ALK-Positive Lung Cancer
Featuring a discussion on the management of ALK-positive lung cancer with Dr Ross Camidge, Dr Justin Gainor, Prof Solange Peters and Prof Ben Solomon, moderated by Dr Neil Love.
-
2
Oncology Today with Dr Neil Love: Management of HER2-Altered Non-Small Cell Lung Cancer?
Featuring a discussion on targeted therapy for HER2-altered non-small cell lung cancer with Dr Bob Li, moderated by Dr Neil Love.
-
1
Oncology Today with Dr Neil Love: Management of Metastatic Non-Small Cell Lung Cancer without an Actionable Mutation
Featuring a discussion on new and emerging data in the management of NSCLC without an actionable mutation, with Dr Edward Garon, moderated by Dr Neil Love.
We're indexing this podcast's transcripts for the first time — this can take a minute or two. We'll show results as soon as they're ready.
No matches for "" in this podcast's transcripts.
No topics indexed yet for this podcast.
Loading reviews...
ABOUT THIS SHOW
Featuring one-on-one interviews conducted by Dr Neil Love, this series bridges the gap between research and patient care by providing medical oncologists, hematologists and hematology/oncology fellows ongoing access to the perspectives and opinions of national and international research leaders with an expertise in thoracic oncology.
HOSTED BY
Dr. Neil Love
Loading similar podcasts...
Frequently Asked Questions
How many episodes does Lung Cancer Update have?
Lung Cancer Update currently has 50 episodes available on PodParley. New episodes are automatically indexed when they're published to the podcast feed.
What is Lung Cancer Update about?
Featuring one-on-one interviews conducted by Dr Neil Love, this series bridges the gap between research and patient care by providing medical oncologists, hematologists and hematology/oncology fellows ongoing access to the perspectives and opinions of national and international research leaders...
How often does Lung Cancer Update release new episodes?
Lung Cancer Update has 50 episodes. Check the episode list to see recent publication dates and frequency.
Where can I listen to Lung Cancer Update?
You can listen to Lung Cancer Update on PodParley by clicking any episode. We provide an embedded audio player for direct listening, and you can also subscribe via your preferred podcast app using the RSS feed.
Who hosts Lung Cancer Update?
Lung Cancer Update is created and hosted by Dr. Neil Love.
URL copied to clipboard!